This Indefinite Delivery Contract (IDC) was awarded by the National Cancer Institute (NCI), a civilian agency, to Infinity Biologix LLC, a for-profit limited liability company, to acquire Genome Characterization Center (GCC) services. The purpose is to perform high-resolution, systematic, and comprehensive characterization of cancer-related genomic alterations across multiple cancer types in support of NCI's cancer genomics research initiatives. The contract has a ceiling value of $149,173,285...
The National Cancer Institute (NCI) awarded an Indefinite Delivery Contract (IDC), Contract No. 75N91025D00009, to the University of Southern California (USC) to provide Genome Characterization Center (GCC) services. The purpose of this multiple-award IDC is to acquire comprehensive sequencing and array platforms, including whole exome sequencing, to support NCI's cancer genomics research programs. The GCCs will receive biomaterials from a centralized Biospecimen Processing Center and perform...
The National Cancer Institute (NCI) has awarded an Indefinite Delivery Contract (IDC) valued at $149,173,285 to the New York Genome Center, Inc. (NYGC) for Genome Characterization Center (GCC) services. The purpose of this contract is to acquire comprehensive sequencing and array platforms for large-scale, high-resolution genomic characterization of cancer samples. The contract is a multiple-award IDIQ with a period of performance through January 12, 2030. Under this vehicle, NYGC will receive...
The National Cancer Institute (NCI) has awarded an Indefinite Delivery Contract (IDC), valued at up to $149,173,285, to The Washington University to provide Genome Characterization Center (GCC) services. The purpose of this multiple-award contract is to acquire comprehensive sequencing and array platforms, including whole exome sequencing, to support NCI's cancer genomics research initiatives. The contract covers four primary service pools: high-throughput DNA sequencing, high-throughput RNA...
This Indefinite Delivery Contract (IDC) was awarded by the National Institutes of Health (NIH) National Cancer Institute (NCI) to The Broad Institute, Inc., a non-profit biomedical and genomic research organization. The $49.8 million IDC supports the NCI Genomic Characterization Centers and provides comprehensive genomic sequencing, data analysis, and other advanced computational biology services to NCI institutes and centers. Under the IDC, The Broad Institute has been awarded multiple task...
The National Cancer Institute (NCI), part of the National Institutes of Health within the Department of Health and Human Services, has awarded an Indefinite Delivery/Indefinite Quantity (IDIQ) contract to Azenta US Inc., doing business as Brooks Life Sciences Inc., for the provision of genomic characterization services to support the NCI's Center for Cancer Genomics research programs. The IDIQ contract has a $49,832,452 ceiling value and a period of performance from August 31, 2019 through...
This Indefinite Delivery Contract (IDC) with ID 75N91018D00009 was awarded by the National Cancer Institute (NCI), part of the Department of Health and Human Services (HHS) National Institutes of Health (NIH), to the Public Health Institute (PHI), a non-profit organization. The $500,000,000 contract, with a period of performance ending on April 30, 2028, is part of the NCI's Surveillance Epidemiology and End Results (SEER) program and does not have a set-aside designation. Under this IDC, PHI...
This Indefinite Delivery Contract (IDC) was awarded by the National Heart Lung and Blood Institute, a civilian agency within the U.S. Department of Health and Human Services, to Illumina, Inc., a manufacturer of genetic sequencing and analysis instruments and reagents. The $243,308 single-award contract has a period of performance ending on June 4, 2013. Under this IDC, Illumina provides a range of genomic sequencing systems, consumables, and bioinformatics products to support research and...
The National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services, awarded an Indefinite Delivery Contract (IDC) to ICF Incorporated, L.L.C., a global consulting and technology services firm, to provide a wide variety of non-research and development technical support and data management services to NCI. The single-award IDC has a ceiling value of $149,900,000 and a period of performance through July 31, 2026. Task orders awarded under this IDC include...
This is a single-award Indefinite Delivery Contract (IDC) issued by the National Cancer Institute (NCI), a civilian federal agency, to Cureline Inc., a woman-owned small business. The contract has a total ceiling value of $690,160.80 and is for the procurement of various human tissue samples to support the NCI Cancer Genome Atlas (TCGA) Program. The contract includes a firm fixed-price delivery order with a ceiling value of $212,610.63 for the purchase of breast ductal, colon, head and neck,...
This indefinite delivery contract (IDC) was awarded by the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services, to Seqmatic, LLC, a minority-owned, Asian-Pacific American-owned small business. The purpose of this $149.17 million multiple-award IDC is to acquire genome characterization center (GCC) services for comprehensive sequencing and array platforms, including whole exome sequencing, to support NCI's cancer genomics research initiatives. Under this contract, Seqmatic will receive cancer biomaterials, operate genome characterization pipelines, perform quality control, and deliver data to the NCI Genomic Data Commons. The contract has a period of performance through January 2030 and was not set aside for any socioeconomic category. This IDC was competed under NAICS code 541380, Testing Laboratories and Services, with a size standard of $16.5 million.
The original solicitation was a small business sources sought notice to identify qualified small businesses, including HUBZone, service-disabled veteran-owned, 8(a), women-owned, and small disadvantaged businesses, that are capable of performing the GCC services. The government may issue a request for proposals to award up to 16 IDIQ contracts, with up to 4 awards per service pool covering high-throughput DNA sequencing, high-throughput RNA sequencing, epigenetic characterization, and single-cell/single-nuclei sequencing. The objective is to enable systematic and comprehensive characterization of cancer-related genomic alterations to facilitate disease-relevant discoveries.